SCIENTIST HOME FUTURE HEALTH LTD

SCIENTIST HOME FUTURE HEALTH LTD

OOTC:SHFH
1.70
USD
0.00
(0.00%)
-0.02EPS
45.06MMarket Cap
SCIENTIST HOME FUTURE HEALTH LTD
OTC:SHFH
(OTC Markets)

Recent

price

1.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2024
2025
TTM
USD
- -
0.01
0.02
Revenue per Share
- -
-0.01
-0.02
Basic EPS, GAAP
- -
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
- -
Book Value per Share
- -
- -
- -
Tangible Book Value per Share
24
24
24
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
-113.56
-99.94
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
-113.56
-99.94
Profit Margin (%)
- -
- -
- -
Working Capital
- -
- -
- -
LT Debt
- -
- -
- -
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
- -
- -
45

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-1,983.57%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
-0.01
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Scientist Home Future Health Ltd. is a healthcare and wellness company engaged in the retail distribution of nutritional dietary supplements, specialized topical creams, and the provision of preventive health screening and rehabilitation services. Operating through two core business segments, Retail Trading and Healthcare Services, the company develops and commercializes wellness solutions focused on degenerative diseases, chronic conditions, and preventive personal care. Its product portfolio comprises dietary and wellness supplements, including hydrolyzed collagen formulations, gelatin hydrolysate powders, joint and bone health supplements, cardiovascular support capsules, blood pressure regulators, uric acid management formulas, prostate support products, and neurological health supplements; therapeutic topical creams and ointments, including spermaceti-based creams, cetylated fatty acid formulations designed for joint mobility and muscular relief, and anti-inflammatory skincare preparations. Within its service operations, the company provides comprehensive physical check-up examinations; routine diagnostic health screenings; personalized wellness consultations; and interdisciplinary rehabilitation programs tailored for geriatric populations, athletes, and health-conscious consumers. Incorporated in Nevada in July 2024, Scientist Home Future Health Ltd. maintains its principal executive headquarters in Kwun Tong, Hong Kong, and conducts its primary commercial operations throughout Hong Kong and broader Asian markets primarily through its wholly owned subsidiary, Scientist Home Future Health Limited (Hong Kong). In recent developments, the company established its public market presence on the U.S. Over-the-Counter market under the ticker symbol SHFH following its corporate organization. Furthermore, the company expanded its clinical development and therapeutic scope by entering into a strategic investment agreement for an evidence-based nutritional therapy targeting severe eczema, securing an initial equity stake with milestone-contingent expansion rights following positive clinical trial outcomes, while actively scaling its retail distribution channels and marketing infrastructure across regional Asian markets.